投稿指南

《药学学报》投稿须知

 

点击下载投稿注册表

 
     《药学学报》是由中国药学会、中国医学科学院药物研究所共同主办的药学综合性学术类月刊,主要报道药学各学科领域基础和应用基础研究的原始性、创新性科研成果,面向国内外公开发行,是中国科技核心期刊,中文核心期刊,被国内外主要检索系统收录。本刊荣获首届国家期刊奖,入选中国期刊方阵双高 (高知名度、高学术水平) 期刊,荣获第届国家期刊奖百种重点科技期刊、第届中国科技优秀期刊奖二等奖以及第二届中国出版政府奖期刊奖提名奖,14年被评百种中国杰出学术期刊连续6获“中国最具国际影响力学术期刊”称号,2013年、2017年两度入选全国“百强科技期刊”

1  稿件内容

刊登的稿件包括综述与述评、研究论文、研究简报和新药发现与研究实例简析等。来稿要求论点明确、数据可靠、结构严密、层次分明、文字精炼。

综述与述评  对当前药学的研究热点和前沿领域进行总结、评述,并结合作者在本领域的工作发表见解。

研究论文  报道药学领域具有原始性和创新性的研究成果。

研究简报  报道药学领域具有原始性、创新性的阶段性研究成果。

新药发现与研究实例简析  以药物化学视角, 对有代表性的药物的成功构建, 加以剖析和解读。

2  投稿要求

作者可以通过登录我刊网站上传稿件或通过电子邮件将稿件发送至编辑部投稿 (网址:http://www.yxxb.com.cn;邮箱:yxxb@imm.ac.cn),并提供: 作者工作单位、地址、邮政编码、电话、传真、E-mail地址 (来稿作者多于1位时,请指定1位通讯联系人) 稿件的电子版,包含中、英文摘要及关键词。编辑部收到电子投稿后将在3日内通知通讯作者稿件编号。作者再将加盖了单位公章的介绍信或投稿注册表扫描后发邮件至编辑部。投稿注册表可从网上 (http://www.yxxb.com.cnwww.imm.ac.cn/acta.asp) 下载。

来稿请勿一稿两投 (以研究通讯形式发表过或在学术会议上宣读过的论文,可在充实内容后以研究论文形式发表)。来稿凡属基金项目、国家攻关项目,请写明项目编号,标注在首页脚注。

3  稿件审理

评审  来稿一经受理,即发稿件回执,并告知稿件编号。一般1个月左右通知作者稿件审理情况。经评审后,编辑部负责转达审稿人意见 (包括退稿通知)。作者应及时按编辑部要求修改,将修改稿、回修通知单及修改说明一起在网站上传或通过E-mail发回编辑部。修改稿在1个月内不返回编辑部者,除特殊情况外,作自行退稿处理。

定稿  稿件通过评审后,发出正式录用通知及版权转让协议书。作者将版权转让协议书签字盖章后,通过E-mail发回编辑部。依照《著作权法》有关规定,编辑部对来稿有删改权。

校样  文章发表前,作者将收到校样、版面费通知。请作者仔细校对,并将修改意见直接标在校样上。作者在收到校样后3天内将修改后校样E-mail发回编辑部,接到收费通知后将版面费汇到编辑部,并按通知要求提供相关信息。

来稿一经发表,酌致作者稿酬,并免费赠送当期期刊2册,电子版单行本将通过E-mail发给通讯作者和第一作者。

4  稿件准备

稿件 (包括题名、作者及单位地址、摘要、关键词、正文、参考文献、图、表格等) 1.5倍行距、宋体 (英文字体用Times New Roman)、小四号字,并标注页码以利于编辑和修改。

题名  简明确切地反映论文的特定内容,一般不超过30字,不得使用不常见的外来语、缩写词、符号、代号和商品名称,尽可能不出现数学式和化学式。英文题名应与中文题名含义一致。

作者及单位地址  文稿的作者应是参与来稿专题研究工作的主要科技人员,应对全文的内容负责,并能回答文中的问题,是论文的法定著作权人和责任者。作者姓名间用逗号分开,应注明通讯作者 (*标出) 及联系方式 (电话、传真和E-mail,写在首页脚注,通讯作者负责与编辑部的联络)。若署名有变动,应有单位证明信。对本文有贡献的其他人员,如协助工作或提供资料、材料者,可放在文后致谢项,对文稿帮助审阅修改者则不列入。作者的汉语拼音姓 (全大写) 在前,名 (首字母大写,双名间加-) 在后,如:刘锡安写为LIU Xi-an。外国作者的姓名写法遵从国际惯例。不同单位的作者在其右上角用12……”标出,并在其工作单位前相应标出12……”。作者的中英文单位名称要写全称,并附省、市名及邮政编码 (英文摘要中加China,不用附省名)

摘要  论文需要同时提供中文和英文摘要。摘要以提供论文的内容梗概为目的,不加评论和补充解释。简明、确切地论述研究目的、原理和结论,具有相对独立性。中文和英文摘要均要求采用报道性 (资料性) 摘要类型。具体要求:中英文摘要均为一段式,内容具体,结果中需要提供关键数据。当研究对象为人或动物时,作者应声明符合人体试验伦理学标准或动物实验伦理学标准,并得到伦理委员会的批准或患者知情同意。中英文摘要内容基本一致,中文摘要以300字左右为宜,英文摘要结果内容需详细。摘要将由编辑部提供给有关文摘检索刊物编辑部,不另付稿酬。

关键词  列出至少5个中、英文关键词。中文关键词放在中文摘要后,英文关键词放在英文摘要后,中、英文关键词一一对应。关键词宜选自《医学主题词注释字顺表》(MeSH词表) 和《中医中药主题词表》。英文关键词全部用小写 (人名等例外),中、英文关键词之间用分号相隔,结束处不用标点符号。

正文  正文各部分都应简洁明了。结果中层次标题一律用阿拉伯数字连续编号,尽量减少层次;不同层次的数字之间用小圆点相隔,末位数字不加标点符号。如11.11.1.1等。各层次的序号均左顶格起排,后空1个字距接排标题,标题不得排在页末。

(1) 前言  简明扼要地阐明研究的目的、意义,概述本研究的理论依据、思路、实验基础及国内外现状,并附上必要的参考文献。

(2) 实验材料  应说明主要材料来源、品种及规格。药学有关名词以《中华人民共和国药典》(2015年版)、全国自然科学名词审定委员会审定公布的《药学名称》、《化学名词》(科学出版社) 为准。

药名采用国际非专利药名 (International Nonproprietary Names, INN),以《中国药品通用名称》(国家药典委员会办公室编,化学工业出版社,1997) 为准。若为国家食品药品监督管理局批准的新药,则用批准的药名。药名较长时,可用缩写,但需在首次出现时注明,如:蜕皮甾酮 (ecdysteroneECR);少用代号,尽量不用商品名。药名首次出现时应写出英文全称。药名写在剂量前面。

研究对象 (动植物、微生物) 应注明拉丁学名,植物标本应说明鉴定人及存放地点。实验动物应标明清洁级和合格证号。实验动物或人的性别、年龄和实际测得的体重应该用均值±标准差 (± s) 及可信区间表示。当实验以人或动物为研究对象时,作者应当声明。只有符合机构责任委员会的伦理 (道德) 标准或依照1975年制定的赫尔辛基宣言 (1983年修订),才能进行人体实验;动物实验应符合伦理学标准,并得到伦理委员会的批准

(3) 实验方法  尽量简洁明了,数据报道注意有效数字位数和精度。凡文献已有记述的方法,一般可引用文献。对新的或有实质性改进的方法要写明改进处。如果是自己创新的方法,则宜详述,以便他人重复。理论计算中采用的计算程序、来源及计算机型号、语言应予以注明。

(4) 计量单位及符号  计量单位一律采用以国际单位制为基础中华人民共和国法定计量单位(简称法定单位)。请参阅《量和单位》(北京:中国标准出版社)。如:1 M硫酸为1 mol·L-1硫酸,1N硫酸为0.5 mol·L-1硫酸。放射性活度的法定单位为Bq;以前习用单位应换算成法定单位,如1 Ci = 37 GBq1 dps = 1 Bq;放射性核素闪烁计数习用单位cpscpm应改用法定单位s-1min-1表示,换算系数为1。表示微量物质质量分数的ppmpphm等应停用,写成10-610-8。以往用来表示化学位移量值的ppm也应废弃,如δ = 2.5 ppm应写成δ = 2.5μg不用γμm不用μr·min-1不用rpm。转速也可用离心力 g) 表示,可用公式r×n2×11.18×10-6换算,式中r为有效离心半径,n为以r·min-1为单位的转速。例:转速为3 000 r·min-1,有效离心半径为10 cm,则离心力为10×3 0002×11.18×10-6 = 1 006.2 ×gRSD (相对标准偏差) 不用CV (变异系数)A (吸收度) 不用OD (光密度)。某些常用量及其符号,如:比重 (sp grsg)、原子量 (Aw)、分子量 (Mwmw) 等,因不符合有关规定,易与有关符号产生混淆或误解,宜停用,应改用相对密度 (d)、相对原子质量 (Ar)、相对分子质量 (Mr) 等。

(5) 国际代号与缩写  文中尽可能采用国际代号与缩写。如果不是常用缩略词,应在第1次出现时给出定义。如:iv (静脉注射)im (肌内注射)ip (腹腔注射)sc (皮下注射)icv (脑室内注射)ia (动脉注射)po (口服)ig (灌胃)。国际代号不用于无数字的文句中,如每天不写每d,但每天8 mg可写8 mg·d-1

(6) 数字  作为量词与序数词一律用阿拉伯数字,数字符号按国家标准GB3102.11-93执行。如:20世纪80年代,第2卷;作为词表构成定性的词、词组、惯用语、缩略语或具有修辞色彩的语句用汉字,如二倍体、三叉神经痛等。单位符号前的数字最好在0.1~1 000,必要时改用适当的词头符号,如:Mm或以10n10-n表示。数字的增加可用倍数,减少则用分数或百分数表示。年份应写出全称,如1998年不写成98年,2~6%应写为2%~6%5~7×104应写为5×104~7×104(5~7)×1042×3×4 mm应写为2 mm×3 mm×4 mm

有效数字  测量数据不能超过其测量仪器的精密度。任何一个数字,只允许最后一位有误差,前面的位数不应有误差。在一组中的± s,应考虑到个体差异,一般以s1/3来定位。如:(4 820.5 ± 340.8) gs1/3超过100 g,平均值波动在百位,故应写为 (4.8 ± 0.3) kg,过多位数并无意义。又如: (3.819 ± 0.411) mms1/3超过0.1 mm,平均值波动在十分位,故应写为 (3.8 ± 0.4) mm。有效位数以后的数字修约数小于5则舍,大于5则进,如等于5,则前一位数逢奇则进、逢偶则舍。数字修约只可一次完成。

(7) 表和图  图表要设计合理,达到自明,即使只看图表就能大体了解实验内容 (图注和表注应适当简述实验内容)。图表一律用英文 (综述除外) 表达。图表中量和单位应是量的符号在前 (斜体),单位符号在后,其间加一斜线的方式表示,如:t/h (表示以h为法定单位的时间)。图表都应用阿拉伯数字依次编号,只有1个时,仍用11表示。图表分单栏 (8 cm) 和双栏 (10~17 cm) 放置,最大长度不能超过24 cm通栏的图和表最好置于页面的最上方或最下方。

文中的图要求准确、清楚。图中的实验点符号及边框线条粗细为0.2 mm,图中的线条粗细为0.3 mm,要求虚实分明、均匀、清晰。图注应放在图题下面,图题和图注分别打印在图的下方。文中照片 (黑白或彩色) 必须反差鲜明,清晰易辨;如果照片内需标注文字、数字或符号等,请另行打印在纸上,不要在照片上作标记;显微照片内应画长度标尺,必要时以箭头标明上下方位。图中标值要圆整化,图已有标值则坐标轴末尾不应有箭头。谱图一般不用列出;如果用简洁的文字不能完全表达,可列出谱图或其相应片段;文章在解释谱图、谱带的形状、精细结构时,也可列出。曲线一般应经曲线拟合,并尽可直线化,如:通过对数 (lg)、倒数 (reciprocal)、概率单位 (probit) 等转换。

表格用三线表,栏目项不应有空缺。卧表无论双页码或单页码,表方位为顶左底右。表内尽量不用或少用标点符号,数字对齐 (±号对齐,小数点对齐等)。表注依次用abc等表示,写在右上角。表中的内容尽量精炼,源于同一实验数据,经过简单代数运算而得的数值不应列入表内。

(8) 命名  学科名称按国务院 (国函[1987]142) 文件规定,使用全国自然科学名称审定委员会审定公布的各学科名词。化合物命名参见中国化学会编制的有机化学命名原则(科学出版社,1983) 无机化学命名原则(科学出版社,1980)以及含杂元素单环化合物HantschWidman命名系统修订规则(有机化学,1984161)。这些规则中没有规定的命名,参见IUPAC有关规则。对于一些特殊的化合物,如:甾体、蛋白质、核酸、糖类、环芳烃等也允许使用半系统命名法,但要符合传统习惯。对于复杂的化合物,难以用系统命名法命名或名称太长,可以采用含糊词,如:23氨基酸14

(9) 化合物表征  对于已知化合物,其来源 (或合成方法)、结构表征数据的参考文献都应提供。发表文献中未报道的谱图数据。对于新化合物,应以标题形式列出,并提供相应的鉴定数据和纯度,一般包括1H NMR (13C NMR)IRMS、元素分析 (HRMS)1H NMR13C NMR数据应完全提供。红外、质谱数据不必完全列出,只列出重要官能团的红外吸收、特殊结构的质谱片段。元素分析鉴定 (CHN),分析数据误差范围为 ± 0.4%,列出元素组成和CHN的实测值和计算值。高分辨质谱 (HRMS) 应列出元素组成及其相应实测值和计算值 (在误差范围内)。外消旋化合物的比旋光度用[α]tλ = (±) Value (csolv.) 表示。λ表示测定波长,通常用钠光D表示,t表示测定温度,c表示测定浓度值 (单位为g/100 mL)solv.表示测定用的溶剂。

化合物的分析结果表达顺序为产率、熔点 (沸点)、旋光度、紫外、红外、核磁光谱、质谱和元素分析 (或高分辨质谱)

(10) 统计学方法  用适当的统计学方法对实验结果进行分析,如参数检验法 (t检验、u检验、F检验等)、非参数检验 (拟合优度检验、成对资料的符号检验、秩和检验等)、方差分析、相关与回归分析等。同组数据以均值±标准差 (± s) 表示,并注明实验观察的例数 (n)ED50 (LD50, IC50) 应计算其95%置信区间,并作probit分析 (BlissFinney分析)。显著性结果以*P<0.05, **P<0.01, ***P<0.001 vs A; P<0.05, △△P<0.01, △△△P<0.001 vs B表示。

(11) 结果与讨论  简洁明了、条理清楚、层次分明。凡用文字已能说明的问题,尽量不用表和图。如用表和图,则文中不需重复其数据,只需强调或摘述其主要发现。同一内容既有图又有表,则二者取其一,能合并者尽量合并。讨论部分应简明扼要、重点突出,主要阐述研究的新发现及对结果的分析,不重复引言及结果中已叙述的内容,避免不成熟的论断。

(12) 致谢  作者对文章作出过贡献的组织或个人予以感谢,放在文章最后。

参考文献  以作者亲自阅读过的近期发表的主要原始文献为限,不能引用其他文章中引用的但未经核对原文的文献。在引文处按引用文献出现的先后顺序用阿拉伯数字依次编号,将序号置于方括号内,以上标形式放置。参考文献著录按文章中引用的顺序依次排列,每条著录项目应齐全,对相同项目不得用同上ibid表示。所引参考文献全部用英文表示,不能用中文、日文、俄文等。中文文献后加圆括号注明中文专著、论文集、学位论文、报告或期刊名称,以便中国科学引文数据库收录。已被采用而尚未刊出的稿件可列为参考文献,但在期刊名后用括号注明in press。作者对所引文献的准确性和完整性负责。

参考文献中,题名后用方括号加注文献类型标识 (普通图书:M,会议录:C,汇编:G,报纸:N,期刊:J,学位论文:D,报告:R,标准:S,专利:P)。文献类型标识是由[文献类型标识/载体类型标识]组成。电子文献类型标识:数据库 (DB),计算机程序 (CP),电子公告 (EB);载体类型标识:磁带 (MT),磁盘 (DK),光盘 (CD),联机网络 (OL)。如 [DB/OL]——联机网上数据库,[M/CD]——光盘图书。中文书名和期刊名后加括号注明中文书名和期刊名。文献作者3人以下,全部列出;3人以上,只列出前3名,其后加et al;姓在前,名缩写在后,作者之间用分开。期刊名缩写参照Chemical Abstract Service Source Index (CASSI)

参考文献著录格式如下:

(1) 专著 (普通图书、论文集、会议录、科技报告及学位论文等)

[序号] 主要责任者. 题名: 其他题名信息 [文献类型标识], 其他责任者. 版本项. 出版地: 出版者, 出版年: 引文页码 [引用日期]. 获取和访问路径.

例:

[1]      Cong PZ, Su KM.  Analytic Chemistry Handbook: Vol 9 (分析化学手册: 第九卷) [M].  2nd ed.  Beijing: Chemical Industry Press, 2000: 726.

[2]      Bernstein J.  Polymorphism in Molecular Crystals [M].  Oxford: Clarendon Press, 2002: 435-439.

[3]      Shi Y, Yang Y, Lei PS.  Proceeding of the 2002 Chinese Pharmaceutical Association Annual Symposium (2002年中国药学会学术年会论文集) [C].  Guilin: Guilin Chinese Pharmaceutical Association Press, 2002: 1170.

[4]      World Health Organization.  Factors Regulating the Immune Response: Report of WHO Scientific Group [R].  Geneva: WHO, 1970.

[5]      Sun YM.  Preclinical Pharmacokinetic Study of Glufosfamide (葡磷酰胺临床前药物代谢与动力学研究) [D].  Shenyang: Shenyang Pharmaceutical University, 2006.

(2) 专著中的析出文献

[序号] 析出文献主要责任者. 析出文献题名 [文献类型标志]. 析出文献其他责任者//专著主要责任者. 专著题名: 其他题名信息. 版本项. 出版地: 出版者, 出版年: 析出文献页码 [引用日期]. 获取和访问路径.

例:

[6]      Ada G .  The immunology of vaccine [M] // Plotkin SA, Orenstein WA. Vaccines. Philadelphia: W.B. Saunders Company, 1999: 28-39.

[7]      Zhang ZX.  UV spectrum analysis [M] // An DK. Pharmaceutical Analysis (药物分析). Jinan: Jinan Press, 1992: 5-18.

[8]      Liu J, Liu CS, Wei SL.  The review of medicinal constituents and pharmacological activities of Rhei Radix et rhizoma [C] // China Association of Traditional Chinese Medicine Tenth Identification of Chinese Academic Proceedings (中华中医药学会第十届中药鉴定学术会议论文集).  Xi’an: China Association of Chinese Medicine, 2010: 334-340.

(3) 连续出版物 (期刊、报纸等)

[序号] 主要责任者. 题名: 其他题名信息 [文献类型标志], , 卷-年, . 出版地: 出版者, 出版年 [引用日期]. 获取和访问路径.

例:

[9]      American Association for the Advancement of Science. Science [J]. 1883, 1(1)-. Washington, D.C.: American Association for the Advancement of Science, 1883-.

(4) 连续出版物中的析出文献

[序号] 析出文献主要责任者. 析出文献题名 [文献类型标志]. 连续出版物题名: 其他题名信息, , : 页码 [引用日期]. 获取和访问路径.

例:

[10]   Zhao B, Fan YC, Wang XQ, et al.  Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes [J].  Acta Pharm Sin (药学学报), 2013, 48: 417-422.

[11]   Leonetti C, Biroccio1 A, Graziani G, et al.  Targeted therapy for brain tumours: role of PARP inhibitors [J].  Curr Cancer Drug Target, 2012, 12: 218-236.

(5) 专利文献

[序号] 专利申请者或所有者. 专利题名: 专利国别, 专利号 [文献类型标志]. 公告日期或公开日期 [引用日期]. 获取和访问路径.

例:

[12]   Wasicak JT, Garvey D, Holladay MW, et al.  7A-Heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission: US, 5733912 [P].  1998-03-31.

[13]   Koseki A, Momose H, Kawahito M, et al.  Compiler: US, 828402 [P/OL].  2002-05-25 [2002-05-28].  http://FF&p= 1&u=netahtml/PTO/search-bool.html&r=5&f=G&1=50&col=AND&d=PG01&sl=IBM.AS.&0S=AN/IBM&RS= AN/IBM.

(6) 电子文献

凡属电子图书、电子图书中的析出文献以及电子报刊中的析出文献的著录项目与著录格式分别按 (1)(5) 中的有关规则处理。除此之外的电子文献根据本规则处理。

[序号] 主要责任者. 题名:其他题名信息 [文献类型标志/文献载体标志]. 出版地: 出版者,出版年 (更新或修改日期) [引用日期]. 获取和访问路径.

例:

[14]   PACS-1: the public access computer systems forum [EB/OL].  Houston, Tex: University of Houston Libraries, 1989 [1995-05-17]. http://info.lib.uh.edu/pacsl.html.

[15]   Christine M.  Plant physiology: plant biology in the Genome Era [J/OL].  Science, 1998, 281: 331-332 [1998-09-23].  http://www.sciencemag.org/cgi/collection/anatmorp.

[16]   Turcotte DL.  Fractals and chaos in geology and geophysics [M/OL].  New York: Cambrige University Press, 1992 [1998-09-23].  http://www.seg.org/reviews/mccorm30.html.

结构式、数学式、反应式和图式  数学式、结构式和反应式采用单栏 (8 cm),图式 (Schemes) 含一系列的化学转换,用单栏、双栏 (17 cm) 均可,尽量采用单栏形式以利于排版。全文的化学结构式 (包含反应式和图式中的结构式) 应用黑体阿拉伯数字编号,化合物编号应以行文中出现的先后顺序编号。为缩短出版周期,请提供规范的化学结构式,要求提供的图单栏栏宽10 cm,双栏栏宽21 cm。请尽量采用ChemDraw画反应式,如果用ChemIntoshChemWindowsISIS等其他画图软件,也符合编辑部要求。

5  注意事项

为适应我国信息化建设需要,扩大学术交流渠道,本刊已加入国内外著名数据库。稿件一经录用,将同时被数据库收录,作者著作权使用费与本刊稿酬一次性给付。如作者不同意收录,请在投稿时声明,否则将视为同意。此投稿须知同时发布在http://www.yxxb.com.cn网站,请查阅。

 

(20191月修订)

 

 

Information for Authors

 

Acta Pharmaceutica Sinica started its publication in July 1953 following its predecessor “Chinese Journal of Pharmaceutical Sciences” which was started in 1936.  Acta Pharmaceutica Sinica, published monthly, is an official journal of the Chinese Pharmaceutical Society and is undertaken by the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College.  It focuses on the current original articles, rapid communication and reviews on all aspects of pharmaceutical sciences and related areas.  It is indexed in Chemical Abstracts, Index Medicus Biological Abstracts, Centre for Agriculture and Bioscience International, Current Bibliography on Science and Technology, Excerpta Medica, Index of Copurnicus, International Pharmaceutical Abstracts, Cambridge Scientific Abstracts, Chinese Pharmaceutical Abstracts, Abstracts of Chinese Medicine, and many other abstracting and indexing services.  Acta Pharmaceutica Sinica is one of top 100 of Chinese academic journals.  It won the first national prize for Chinese journals.

 

1  Scope of submitted manuscripts

Acta Pharmaceutica Sinica invites original articles and review papers dealing with pharmaceutical sciences.  All aspects of pharmacology, pharmaceutics, medicinal chemistry, natural products and pharmaceutical analysis are appropriate.

Review articles  The articles should encompass the new and important aspects of study and describe the research results.

Original articles  New, significant, innovative, and original findings are suitable as original articles.

Communication  The articles should contain new and important information that would be of interest to readers, making urgent publication desirable.

2  Submissions of manuscripts

You must register a form (http://www.yxxb.com.cn) before you submit a paper.

Acta Pharmaceutica Sinica has operated an online submission and peer-review system since 2007.  The system is easy to use and allows authors to submit papers online and track the progress of their papers through the editorial process (www.yxxb.com.cn).

Prior or duplicate publications are not accepted.  All manuscripts, especially data, must not be published or submitted for publication elsewhere.  The authors should make a full statement on submission about all submissions.  Submitted manuscripts should be accompanied by a covering letter giving details of 1) the title of the manuscript;   2) a statement that the manuscript has not been published in part or whole (except in the form of abstract) or is under consideration for publication elsewhere in any language.

The source of financial grants and other funding must be acknowledged.  The contribution of colleagues or institutions should also be acknowledged.

3  Peer-reviewed

3.1  Manuscript receipt

Upon the receipt of the manuscript, the editorial office will immediately assign a code number, which is strongly recommended to use in subsequent correspondence.  An acknowledgement of receipt letter will be sent to the corresponding author.  After pre-reviewed by the editors, most of the submitted manuscripts will be sent to expert referees for evaluation.  All manuscripts are subject to editorial modifications.

3.2  Revision

When the authors receive comments they should revise the manuscript, answer the comments one by one and indicate the page and line of each correction immediately.  A revised manuscript will be considered a new submission if it is not returned to the editorial office within one month.  Revised versions labeled with the manuscript code number should be sent by mail.

3.3  Rejected manuscripts

If a manuscript is not accepted for publication, the authors will receive a decision letter along with the reviewer’s comments.

3.4  Proofreading

Checking the proofs is solely the authors’ responsibility.  Corrections are restricted to printer’s errors.  Answer all queries (in the interests of accuracy) on the proof.  Make all corrections legibly (preferably by typing) in the margins. Use universally accepted proofreader’s signs and symbols.  If the authors feel that it is very important to include new information, insert it as a “Note added in proof” with the permission of the editorial office.

3.5  Copyright assignment form

Papers accepted for publication become copyright of Acta Pharmaceutica Sinica and authors will be asked to sign a transfer of copyright form.  In signing the transfer of copyright it is assumed that authors have obtained permission to use any copyrighted or previously published material.  All authors must read and agree to the conditions outlined in the transfer of the copyright form, and must sign the form.  Articles will not be published until a signed copyright assignment form has been received.

You should return the proof and copyright assignment form to the editorial office within three days after they are received.  If the time limit is exceeded, the publication of the article might be postponed.

4  Organization of the manuscript

4.1  Title

The title must be informative, specific, and brief (<30 words).  Words should be chosen carefully for retrieval purposes.

4.2  Authors and affiliation

Authors should have participated sufficiently in the work to take public responsibility for the content.  Capitalize all the letters in the surname, spell out the given name in full, for example: LIU Xi-an.  Any changes in authorship must be approved in writing by all authors.  Please indicate the corresponding author’s telephone number, fax number and E-mail address in the footnote.  An asterisk (*) should be added to the right of the corresponding author’s name.  The affiliation is the institute or laboratory where the work was done.  When there are two or more authors who belong to more than one affiliation, should list out all the affiliations.

4.3  Abstract

The abstract should describe the aim, general methods, results, and conclusion of the paper.  The abstract must be a single paragraph. Animal experiments should adhere to instructions for the care and use of animals provided by the appropriate Ethics Committee. Human experiments may be performed only in accordance with the ethical standards and permission of the responsible committee of the institution at which the work was carried out.

4.4  Key words

Provide 5−8 key words or phrases.  Use terms recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH) browser list at http://www.nlm.nih.gov/mesh/meshhome.html.  If a suitable MeSH term is not available, a more general term suitable for indexing may be used.

4.5  Text

4.5.1  Introduction summarizes a concise study background using references.  The purpose of carrying out the study should be described clearly.

4.5.2  Materials provide main drugs, chemicals and instruments including manufacturers and specifications.

Drug nomenclature  International Nonproprietary Names (INN) or generic names should be employed whenever possible.  The first letter of the drug name should be lowercase for INN or generic names, but capitalized for proprietary names.

Species nomenclature  The scientific name [genus, species (in italics) and authority] for all plants, animals and microorganisms, should be given.  Simple chemical names may be used in certain places.

Experimental subjects indicate the grade of your animals and give the certificate number of the animal breeder.  Rats and mice of at least Grade II should be reported.  The sex, age, and body weight of tested animals or humans should be expressed as mean, standard deviation, and total range.  Animal experiments should follow the instructions for the care and use provided by the institution.  Human experiments may be performed only in accordance with the ethical standards provided by the responsible committee of the institution by which the work was carried out.

4.5.3  Methods should offer technical information to allow the experiments to be repeated. Describe new methods or modifications.

4.5.4  Quantities, units, and numerical values  SI units must be used.  For example: length (m, cm, mm, μm, nm), mass (kg, g, mg, μg), volume (L, mL, μL), time (s, min, h, d), temperature (, K), radiation (Bq, dpm), concentration [mol·L−1, mmol·L−1, mg·mL−1, μg·mL−1, % (v/v), % (w/v)].  Physical quantities are printed in italic type, for example, t/h (t/h).  A solidus (/) should not be followed by a multiplication sign or a division sign unless parentheses are inserted to avoid any ambiguity.  When an Arabic number precedes an SI unit, the unit symbol should be used rather than the full name of the unit, for example, 1 min (one minute), 2 h (two hours).  No unit is required for relative molecular mass (Mr).

4.5.5  Abbreviations must be spelled out in full at their initial appearance, followed by the abbreviation in parentheses.  The routes of administration may be abbreviated, for example, intravenous (iv), intramuscular (im), intraperitoneal (ip), subcutaneous (sc), intracerebroventricular (icv), intraarterial (ia), per os (po), intragastric gavage (ig).

4.5.6  Effective digits are determined by the variation within the sample, which is one-third of the standard deviation.  For example: (4.8 ± 0.3) kg (not 4820 ± 340.8 g), 2% − 6% (not 2 − 6%), 5×104 − 7×104 (not 5 − 7×104), 2 mm × 3 mm × 4 mm (not 2 × 3 × 4 mm).

4.5.7  Tables and figures should be self-explanatory (intelligible without reference to the text).  Avoid repetitions of data in the text, tables, and figures.  Tables are preferable to figures, especially if the figure is a simple histogram.  Indicate the number and character of observations and subjects.

Tables are numbered consecutively with Arabic numerals.  The title should immediately follow the table number, at the head of the table.  Each table should give each column a short or abbreviated heading, in which the quantity and the unit are usually separated by a solidus (/).  More than one solidus is not allowed in a single item.  If an experimental condition is the same for all of the tabulated experiments (e.g. the n), give this information in a statement accompanying the table.

Figures  Freehand or typewritten lettering is unacceptable.  Choose the intervals so that the interpolation will permit accurate evaluation of the points.  The symbols and curves can be identified in the figure itself or in the legend.  Broader lines should be drawn for curves than for the axes.  Combine related curves in a single figure when possible.  A composite of curves will save space and convey more information.  Do not extrapolate the curves, nor extend the axes far beyond the contents.  When feasible, curves should be transformed into straight lines with the aid of logarithm, reciprocal, probit, logit, etc.  Indicate the scales by short index lines.  Repeat these index lines on the opposite sides unless more than one scale is used.  In general, the heightwidth ratio of figures should be 23.

Photographs must be of the highest quality with good contrast.  Color photographs are welcome.  With photomicrographs, crop to show only the essential parts: a second small photomicrograph at higher magnification is usually more informative than a single large one. Scale markers (e.g. 1 μm) should be put inside the photomicrographs.  Briefly explain the symbols, arrows, numbers, or letters in the illustrations.  Identify the method of staining and magnification of the photomicrographs (e.g. HE stain, ×900).

Maximum width of table and figure should be 8 cm (or 10 − 17 cm for two-column width).  Please use only one size of writing in any one diagram.

4.5.8  Nomenclature  used for chemical compounds shall be in accordance with the nomenclature rules formulated by IUPAC.  Alternatively, naming may conform to the nomenclature in the index of Chemical Abstracts or the Ring Index.  Stereochemical information (cis, Z, R, etc.), locants (N-methyl, α-amino), and symmetry designations (C2v) should also be italicized.  Chemical formula (e) should be numbered with boldface Arabic numerals (e.g. 1).  Abbreviations such as Me, Et, nBu, iPr, sBu, tBu, and Ph (not φ) may be used.  General substituents should be indicated by R1, R2 (not R2, which means 2R), or R, R′.  The spatial arrangement of the substituents should be indicated by hatched lines or a wedge.  A minus sign must be as long as the crossbar of a plus sign.

4.5.9  Confirmation of structure  Adequate evidence to establish structural identity must accompany all new compounds that appear in the experimental section of original articles and communications.  Generally, the physical and chemical parameters of new compounds should be given in the following order: m.p. (b.p.), [α]D; UV-vis λmax; IRυ, 1H NMR and 13C NMR; MS m/z; elemental analyses or HRMS data.  List only IR that is diagnostic for key functional groups.

4.5.10  Statistical methods should be described when they are used to verify the results.  Suitable techniques should be chosen for the statistical treatments, for example, t-test (group or paired comparisons), chi-square test, Ridit, probit, regression (linear, curvilinear, or stepwise), correlation, analysis of variance (ANOVA), analysis of covariance, etc.  Only homogeneous data can be averaged.  Standard deviations are preferred to standard errors.  Give the number of observations and subjects.

Identify statistical significance by superscripts in front of the probabilities (P): *P < 0.05, **P < 0.01,     ***P < 0.001 vs A; P < 0.05, △△P < 0.01, △△△P < 0.001 vs B.

Values such as ED50, LD50, IC50 should have their 95% confidence limits calculated and compared by weighted probit analysis (Bliss and Finney).  The word “significantly” should be replaced by its synonyms (if it indicates extent) or the P value (if it indicates statistical significance).

4.5.11  Results and discussion emphasize or summarize only important observations; give absolute values, not merely percentages, particularly for the control values; present your results followed by tables or figures; reserve extensive interpretations of the results for the discussion section.  The discussion section should deal with the interpretations of your results.  Emphasize any new and important findings and relate your results to other studies.  Discuss the shortcomings in your experiments.  New hypotheses and recommendations may be proposed when warranted.

4.5.12  Acknowledgments may briefly include acknowledgement of assistance from 1) contributors that do not warrant authorship; 2) technical help; and 3) material support.

4.6  References

References must be verified by the present authors against the original documents.  References are numbered consecutively with Arabic numerals.  When cited in the text, reference numbers are superscript, in brackets.  Avoid using abstracts as references.  “Unpublished data”, “classified periodicals”, and “personal communications” can not be used as references.  Old references should be replaced with updated ones.  Papers accepted but not yet published may be used as references.

The titles of journals should be abbreviated according to “Chemical Abstract Service Source Index (CASSI)”.  All authors should be listed, but if the number of authors exceeds three, first three authors is listed followed by et al.  Examples follow.

Books and other monographs conference proceedings, conference paper scientific or technical report and dissertation

[1]     Bernstein J.  Polymorphism in Molecular Crystals [M].  Oxford: Clarendon Press, 2002: 435−439.

Standard journal article

[2]     Zanzonico PB.  Internal radionuclide radiation dosimetry: a review of basic concepts and recent development [J].  J Nucl Med, 2000, 41: 297−308.

Patent

[3]     Wasical JT, Garvey D, Holladay MW, et al.  7A-Heterocycle substituted hexahydro-1H-pyrrolizine compounds useful in controlling chemical synaptic transmission: US, 5733912 [P].  1998-03-31.

Electronic material

[4]     Christine M.  Plant physiology: plant biology in the Genome Era [J/OL].  Science, 1998, 281: 331−332 [1998-09-23].  http//www.sciencemag.org/cgi/collection/anatmorp.

 

  

                                                                                                                                             Revised Nov 2018